Price$2.64-1.02 (-27.87%)
2026-01-202026-04-23
News · 26 weeks28-60%
2025-10-262026-04-19
Mix1590d
- Insider8(53%)
- Other2(13%)
- Leadership2(13%)
- SEC Filings2(13%)
- Analyst1(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Elmore Robert Ryan4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- ANALYSTH.C. Wainwright initiated coverage on SINTX Technologies with a new price targetH.C. Wainwright initiated coverage of SINTX Technologies with a rating of Buy and set a new price target of $10.00
- PRSINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial ExecutionClinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us
- SECSEC Form 10-K filed by SiNtx Technologies Inc.10-K - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle ImplantMajor clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramic biomaterials and silicon nitride medical device innovation, today announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market. The procedure represents SINTX's entry int
- INSIDERSEC Form 4 filed by SiNtx Technologies Inc.4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- INSIDERDirector Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- INSIDERDirector Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- INSIDERDirector Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial PlatformsAppointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev
- INSIDERSEC Form 4 filed by Chief Financial Officer Trask Kevin4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- INSIDERSEC Form 4 filed by Chairman, President and CEO Olson Eric K.4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- INSIDERSEC Form 4 filed by Chief Investment Officer Honigblum Gregg R.4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- PRSINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company's participation comes at an important stage in its evolution, following a period of operational restructuring, enhanced financial discipline, and a renewed strategic focus on its core medical-technology platforms. With a more streamlined cost structure, greater visibility into its balance-sheet, and sev
- SECSEC Form EFFECT filed by SiNtx Technologies Inc.EFFECT - Sintx Technologies, Inc. (0001269026) (Filer)
- SECAmendment: SEC Form S-3/A filed by SiNtx Technologies Inc.S-3/A - Sintx Technologies, Inc. (0001269026) (Filer)
- NEWSSidoti Events, LLC's Year-End Virtual Investor ConferenceNEW YORK, NY / ACCESS Newswire / December 9, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day Year-End Virtual Investor Conference taking place Wednesday and Thursday, December 10-11, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links. Presentation Schedule*All Times ESTWednesday, December 10, 2025 (Day 1)8:30-9:00Freightos (NASDAQ:CRGO)Nano-X Imaging, Ltd. (NASDAQ:NNOX)Waterdrop Inc. (NYSE:WDH)9:15-9:45ICF International (NASDAQ:ICFI)L.B. Foster Company (NASDAQ:FSTR)MoneyHero Limited (NASDAQ:MNY)10:00-10:30Vishay Prec
- INSIDERChief Investment Officer Honigblum Gregg R. bought $34,896 worth of shares (8,200 units at $4.26), increasing direct ownership by 4% to 201,067 units (SEC Form 4)4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- PRSINTX Technologies to Participate in Sidoti & Company Investor ConferenceSALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), today announced that management will be presenting at Sidoti & Company's Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: https://sidoti.zoom.us/webinar/register/WN_O_OnAvXpQki63dk_9JbUYw To schedule a one-on-one meeting with SINTX Technologies' management team, please email KCSA Strategic Communications at Sintx@kcsa.com. To be added to the Sintx Technologies email distribution list, please email Si
- INSIDERChief Investment Officer Honigblum Gregg R. bought $255,350 worth of shares (65,000 units at $3.93) and was granted 53,867 shares, increasing direct ownership by 161% to 192,867 units (SEC Form 4)4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific ImplantsMilestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation ("EVONIK"), a global leader in high‑performance polymers, to manufacture the Company's proprietary silicon nitride–PEEK compound (SiN/PEEK) (U.S. Patent No. 10,806,831) engineered for AI‑assisted additive manufacturing of patient‑specific implants that will be produced using equipment already in place at SINTX's U.S.-based production facility. Under the agreement, EVONIK will pr
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational EfficienciesCompany underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™ SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni